Is STERIS Stock Underperforming the Nasdaq?

Core Insights - STERIS plc, based in Mentor, Ohio, specializes in infection prevention products and services, with a market capitalization of $21 billion, offering a range of medical devices including sterilizers and surgical tables [1][2] Company Overview - STERIS is classified as a large-cap stock due to its market cap exceeding $10 billion, highlighting its significant influence in the medical devices industry [2] - The company is a market leader in infection prevention, providing a diverse portfolio that serves as a one-stop solution for healthcare providers, which aids in revenue generation and customer retention [2] Stock Performance - STERIS shares have experienced a decline of 20.4% from their 52-week high of $269.44, reached on January 16, and a 14.8% drop over the past three months, underperforming the Nasdaq Composite's 4.7% losses during the same period [3] - Over a six-month period, STERIS shares fell 14.1%, and over the past 52 weeks, they dipped 3.5%, again underperforming the Nasdaq Composite, which had a 27.8% return [5] - The stock has been trading below its 200-day moving average since early March and below its 50-day moving average since early February, indicating a bearish trend [5] Financial Performance - In its Q3 results, STERIS reported revenue of $1.50 billion, exceeding analyst expectations of $1.48 billion, with an adjusted EPS of $2.53 meeting Wall Street forecasts [7] Analyst Sentiment - Wall Street analysts maintain a reasonably bullish outlook on STERIS, with a consensus "Moderate Buy" rating from nine analysts and a mean price target of $288.43, suggesting a potential upside of 34.4% from current price levels [8]